Frequency of prognostic biomarker testing by LOT and treatments received by patients in informCLL by prognostic biomarker status. (A) FISH cytogenetic testing rates, TP53 mutational status testing rates, and IGHV mutational status testing rates. (B) Treatments received by status of del(17p), TP53 mutation, and IGHV mutation. Proportions may not add up to 100% owing to rounding. ∗Includes del(17p), del(11q), del(13q), and trisomy 12. ^†Patients with unknown testing result (n = 38). ^‡Patients with not evaluable/not specified testing result (n = 25). ^§Patients with not evaluable/not specified testing result (n = 12). CIT, chemoimmunotherapy; CT, chemotherapy; IT, immunotherapy.